Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors

A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Trial Of Cvx-060, A Selective Angiopoietin-2 (Ang-2) Binding, Anti-angiogenic Covx-body, In Patients With Advanced Solid Tumors

The purpose of this study is to determine the safety and tolerability of CVX-060 in patients with advanced solid tumors.

Inclusion Criteria:

• Confirmed advanced solid tumors unresponsive to currently available therapies or for which there is no standard therapy.
• Adequate coagulation, liver, and renal function.
• Candidate for DCE-MRI evaluations.
• ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.

Exclusion Criteria:

• Evidence of significant bleeding problems.
• History of certain gastrointestinal problems including fistula and abscess.
• Chronic, uncontrolled hypertension.
• Patients with any history of primary or metastatic tumor involvement of the brain or with tumors that encase great vessels.